Health and Human Services Department, Food and Drug Administration
The Food and Drug Administration (FDA, Agency, or we) is extending the effective date of the notice published in the Federal Register on May 27, 2026, titled Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661 (91 FR. 31462) (the "May 2026 Notice"), by 90 days. The effective date of the May 2026 Notice is hereby extended from June 26, 2026, to September 24, 2026. This extension is necessary to allow FDA sufficient time to consider issues raised by interested parties following publication of the May 2026 Notice.
Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Food and Drug Administration [Docket No. FDA-1998-P-0083 (formerly 76N-0377); DESI 7661] AGENCY: Food and Drug Administration, Health and Human Services (HHS). ACTION: Notice; extension of effective date. SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is extending the effective date of the notice published in the Federal Register on May 27, 2026, titled Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661 ( 91 FR. 31462 ) (the “May 2026 Notice”), by 90 days. The effective date of the May 2026 Notice is hereby extended from June 26, 2026, to September 24, 2026. This extension is necessary to allow FDA sufficient time to consider issues raised by interested parties following publication of the May 2026 Notice. DATES: The effective date of the May 27, 2026, notice ( 91 FR 31462 ) is extended to September 24, 2026. ADDRESSES: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500 between 9 a.m. and 4 p.m.…
Other Federal Register documents from the same docket.
Citation: 91 FR 38717
